Valuation: OLIPASS Corporation

Market Cap 26.53B 17.56M 15.4M 14.22M 13.14M 24.91M 1.68B 25.41M 171M 66.43M 823M 65.95M 64.5M 2.86B P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 20.34B 13.46M 11.81M 10.9M 10.07M 19.09M 1.29B 19.47M 131M 50.92M 631M 50.55M 49.44M 2.19B EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
158,000
10 years 1,568
Extreme 1568
240,666.67
Manager TitleAgeSince
Chief Executive Officer 54 21/05/2025
Corporate Officer/Principal 34 27/11/2024
Comptroller/Controller/Auditor 67 30/03/2025
Director TitleAgeSince
Director/Board Member 54 27/11/2024
Director/Board Member 34 27/11/2024
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-92.30% 9.27M
-0.63%-3.68%+70.92%+126.05% 56.71B
-2.45%-7.83%+63.92%+83.15% 51.3B
+1.51%+6.38%+23.06%+481.96% 25.26B
+0.56%-3.32%-15.63%-12.22% 23.65B
+3.93%+3.35%+43.09%-2.47% 18.69B
+1.73%+2.96%+40.69%-24.48% 17.71B
+2.34%+12.50%+224.02%+380.99% 17.7B
-0.92%+1.58%+35.79% - 14.26B
+1.43%+2.44%+29.83%+200.03% 14.1B
Average -0.66%-0.97%+51.57%+126.74% 23.94B
Weighted average by Cap. +0.16%+2.20%+58.22%+143.83%

Financials

2021 2022
Net sales 852M 564K 495K 457K 422K 800K 53.99M 816K 5.49M 2.13M 26.42M 2.12M 2.07M 91.71M 2.3B 1.52M 1.33M 1.23M 1.14M 2.16M 146M 2.2M 14.8M 5.75M 71.22M 5.71M 5.58M 247M
Net income -25.13B -16.64M -14.59M -13.47M -12.45M -23.6M -1.59B -24.07M -162M -62.93M -780M -62.48M -61.11M -2.71B -24.17B -16M -14.03M -12.95M -11.97M -22.69M -1.53B -23.14M -156M -60.51M -750M -60.08M -58.76M -2.6B
Net Debt -18.29B -12.11M -10.62M -9.8M -9.06M -17.17M -1.16B -17.52M -118M -45.79M -567M -45.47M -44.47M -1.97B -6.2B -4.1M -3.6M -3.32M -3.07M -5.82M -393M -5.93M -39.92M -15.51M -192M -15.4M -15.06M -667M
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
78
  1. Stock Market
  2. Stocks
  3. A244460 Stock